ClinicalTrials.gg
CompletedNCT07782775Updated Oct 14, 2026

A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants

A Phase 1 interventional study of Efgartigimod PH20 SC via PFS and Efgartigimod PH20 SC via AI in Healthy Volunteer and Healthy Adult Participants, sponsored by argenx. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by argenx · Phase 1, Interventional, and Treatment

Updated Oct 14, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The aim of this study is to compare the amount of efgartigimod in the blood over time after it is injected via Prefilled syringe (PFS) and Autoinjector (AI).

The study will comprise 2 study periods of 3 weeks each. Each participant receives both efgartigimod PH20 SC AI and PFS treatments, in a different order.

Participants will be in the study for up to approximately 9 weeks.

02

Conditions studied

  • Healthy Volunteer
  • Healthy Adult Participants
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least the local legal age of consent and aged 18 to 55 years, inclusive, when signing the ICF.
  • Has a body weight between 50 and 100 kg and a between 18 and 30 kg/m2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Has any current or past medical or psychiatric condition that, in the investigator's opinion, would confound the study results or put the participant at undue risk.
  • Has received any medications, including nonprescription and prescription medications, within 2 weeks before the first IMP administration, except for hormonal and hormone replacement therapy in female participants. The occasional use of acetaminophen or ibuprofen is allowed.
  • Previously participated in an efgartigimod clinical study and received at least 1 dose of IMP.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Treatment sequence 1

    Participants randomized to receive Efgartigimod PH20 SC via AI in period 1 and Efgartigimod PH20 SC via PFS in period 2

    Biological: Efgartigimod PH20 SC via PFS · Biological: Efgartigimod PH20 SC via AI

  • Experimental
    Treatment sequence 2

    Participants randomized to receive Efgartigimod PH20 SC via PFS in period 1 and Efgartigimod PH20 SC via AI in period 2

    Biological: Efgartigimod PH20 SC via PFS · Biological: Efgartigimod PH20 SC via AI

Interventions

  • BiologicalEfgartigimod PH20 SC via PFS

    Subcutaneous injection of empasiprubart via Prefilled syringe (PFS)

  • BiologicalEfgartigimod PH20 SC via AI

    Subcutaneous injection of empasiprubart via Autoinjector (AI)

06

What researchers measure

Primary outcomes

  1. Primary PK parameter: Cmax

    Cmax = maximum observed concentration

    Time frame: Up to 9 weeks

  2. Primary PK parameter: AUC0-inf

    AUC0-inf = area under the curve from time 0 to infinity

    Time frame: Up to 9 weeks

Secondary outcomes

  1. Secondary PK parameter: AUC0-t

    AUC0-t = area under the curve from time 0 to the last measurable time point

    Time frame: Up to 9 weeks

  2. Secondary PK parameter: AUC0-168h

    AUC0-168h = area under the curve from time 0 to 168 hours

    Time frame: Up to 9 weeks

  3. Secondary PK parameter: CL/F

    CL/F = apparent clearance from plasma after extravascular administration

    Time frame: Up to 9 weeks

  4. Secondary PK parameter: Vz/F

    Vz/F = apparent volume of distribution at steady state after extravascular administration

    Time frame: Up to 9 weeks

  5. Secondary PK parameter: Tmax

    Tmax = time to Cmax

    Time frame: Up to 9 weeks

  6. Secondary PK parameter: t½

    t½ = half-life

    Time frame: Up to 9 weeks

  7. Incidence of AEs, SAEs, and AEs leading to efgartigimod discontinuation

    AE = adverse event ; SAE = serious adverse event

    Time frame: Up to 9 weeks

07

Study locations

1 site
  • Altasciences
    Montreal, H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Sep 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 24, 2026
StartActual
Jun 19, 2026
Primary completionActual
Sep 23, 2026
CompletionActual
Sep 23, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 14, 2026
Primary completion
Sep 18, 2026→Sep 23, 2026 (actual)
Oct 14, 2026
Study completion
Sep 18, 2026→Sep 23, 2026 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Completed
    Primary completion Sep 18, 2026→Sep 23, 2026 (now actual)
    Study completion Sep 18, 2026→Sep 23, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07782775
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Jun 19, 2026
Primary completion
Sep 23, 2026
Completion
Sep 23, 2026
Last update
Oct 14, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion